Steady State Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Torrent Pharmaceuticals Limited
ClinicalTrials.gov Identifier:
NCT01634373
First received: June 27, 2012
Last updated: July 2, 2012
Last verified: July 2012

June 27, 2012
July 2, 2012
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01634373 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Steady State Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets
An Open-Label, Randomised, 2-Period, 2-Treatment, 2-sequence, Crossover, Steady State Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets [Test Formulation; Torrent Pharmaceuticals Ltd., India] Versus Seroquel® 300 mg Tablet [Reference Formulation; AstraZeneca, USA] in Schizophrenic Patients.

Objective:

Primary objective was to study Steady-state bioequivalence of Torrent's Quetiapine Fumarate Tablets 300 mg.

Study Design:

Randomized, Two-Way, Crossover, multiple Dose, and Open-Label

Not Provided
Interventional
Phase 1
Not Provided
Schizophrenia
Drug: Torrent's Quetiapine Fumarate Tablets
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Sex: Male of female
  • Age: 25-65 years
  • Patients who are receiving a stable daily dose of quetiapine 300 mg every 12 hourly for atlist one month
  • Patient willing to adhere to the protocol requirements

Exclusion Criteria:

  • Clinically relevant abnormalities in the results of the laboratory screening evaluation.
  • Clinically significant abnormal ECG.
  • Significant orthostatic hypotension (i.e., a drop in systolic blood pressure of 30 mm Hg or more and/or a drop in diastolic blood pressure of 20 mm Hg or more on standing)
  • Concurrent use of antihypertensive medication or any medication that might pre-dispose to orthostatic hypotension.
  • History of allergic reactions to quetiapine or other chemically related psychotropic drugs.
  • Concurrent primary psychiatric or neurological diagnosis including organic mental disorder, severe tardive dyskinesia, or idiopathic Parkinson's disease.
  • Existence of any surgical or medical condition, which in the judgement of the Principal Investigator, might interfere with the absorption, distribution, metabolism or excretion of the drug or likely to compromise the safety of patients.
  • Concurrent use of other drugs known to suppress bone marrow function.
  • HIV, HCV, HBsAg positive.
  • Expected changes in concomitant medications during the period of study.
  • A history of epilepsy or risk for seizures
  • positive urine drug of abuse test at enrollment.
  • A history of alcohol or drug dependence by Diagnostic and statistical manual of Mental disorders IV(DSM-IV) criteria during the 6 month period immediately prior to study entry.
  • A total white blood cell count below 4000/ml, or absolute neutrophil count below 2000/ml
  • Female patients with pregnancy or Breast feeding or intend to become pregnant during the study and not able to follow contraception methods.
  • History of multiple syncopal episodes.
  • Administration any study drugs in last 3 months prior to entry in the study.
  • History of significant blood loss due to any reason in the past 3 months.
  • Any pre-existing bleeding disorder.
Both
25 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
India
 
NCT01634373
PK-08-111
No
Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals Limited
Not Provided
Not Provided
Torrent Pharmaceuticals Limited
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP